Coy et al. 10/712,081

Serial No. : Filed :

November 13, 2003

Page

2

COMPLETE LISTING OF ALL CLAIMS, WITH MARKINGS AND STATUS IDENTIFIERS

(Amendments are illustrated by showing deletions by strikethrough or by [[double brackets]] for deletions of five or fewer characters and additions by underlining)

Claims 1-17 (canceled)

Claim 18 (previously presented): A compound of the formula:

$$R_1$$

$$A^1-D-Cys-A^3-D-Trp-Lys-A^6-Cys-A^8-R_3$$

$$R_2$$

wherein

A¹ is a D- or L-isomer of an aromatic amino acid or is deleted;

A' is an aromatic amino acid;

A⁶ is Thr, Thr(Bzl), Gly, Ser, an Eaa or an aliphatic amino acid:

A⁸ is a D- or L-isomer selected from the group consisting of Thr, Ser, an aromatic amino acid or an aliphatic amino acid;

each of R_1 and R_2 , is, independently, H or substituted or unsubstituted lower alkyl, aryl, aryl lower alkyl, heterocycle, heterocycle lower alkyl, E_1SO_2 or E_1CO wherein E_1 , is aryl, aryl lower alkyl, heterocycle or heterocycle lower alky and said substituent is halo, lower alkyl, hydroxy, halo lower alkyl or hydroxy lower alkyl; and

Filed: November 13, 2003

Page: 3

 R_3 is OH, NH_2 , C_{1-12} alkoxy or $NH-Y-CH_2-Z$, wherein Y is a C_{1-12} hydrocarbon moiety and Z is H, OH, CO,H or CONH,

provided that R_3 , together with the carbonyl group of A^8 attached thereto, are reduced to form H, lower alkyl, or hydroxy lower alkyl;

further provided that a disulfide bond links the sidechains of ${\mbox{A}}^2$ and ${\mbox{A}}^7;$ and

further provided that if A^1 is D-Phe or $p-NO_2-Phe$, A^3 is Phe or Tyr and A^6 is Thr or Val, then A^8 is B-Nal.

19 (previously presented): A compound of claim 44, wherein A¹ is the D- or L-isomer of ß-Nal, o-X-Phe wherein X is H, OH, CH, halo, OCH, NH, CN, or NO, p-X-Phe wherein X is H, OH, CH, halo, OCH, NH, CN, or NO, m-X-Phe wherein X is H, OH, CH, halo, OCH, NH, CN, or NO, F,-Phe, Trp, Dip, 2-Pal, Tyr(Bzl), His, Igl, Tyr(I), Bta, Bip, Npa, or Pal; A' is &-Nal, o-X-Phe wherein X is H, OH, CH, halo, OCH, NH, CN, or NO, p-X-Phe wherein X is H, OH, CH, halo, OCH, NH, CN, or NO, m-X-Phe wherein X is H, OH, CH, halo, OCH, NH, CN, or NO, F5-Phe, Trp, Dip, 2-Pal, Tyr(Bzl), His, Igl, Tyr(I), Bta, Bip, Npa, or Pal; A⁶ is Thr, Ser, Tle, Thr(Bzl), Abu, Ala, Ile, Leu, Gly, Nle, &-Ala, Gaba, or Val; and A^8 is the D- or L-isomer of Thr, Dip, F_5 -Phe, p-X-Phe wherein X is H, OH, CH, halo, OCH, NH, CN, or NO, o-X-Phe wherein X is H, OH, CH₃, halo, OCH₃, NH₂, CN, or NO₂, m-X-Phe wherein X is H, OH, CH, halo, OCH, NH, CN, or NO, Igl, Tyr(Bzl), or ß-Nal.

Coy et al.

Serial No. :

10/712,081

Filed

November 13, 2003

Page

20 (previously presented): A compound of claim 19, wherein A^1 is the D- or L-isomer of ß-Nal, Phe, p-F-Phe, Trp, p-Cl-Phe, or p-CN-Phe; A^3 is Tyr, Tyr(I), or Pal; A^6 is Val, Tle, Nle, Ile, or Leu; A^8 is p-F-Phe, ß-Nal, Tyr, Dip, p-Cl-Phe, Igl, or p-CN-Phe; R_1 is H, CH₃CO, 4-(2-hydroxyethyl)-1-piperazinylacetyl, or 4-(2-hydroxyethyl)-1-piperizineethanesulfonyl; and R_2 is H.

21 (original): A compound of claim 20, wherein A³ is Pal.

22 (previously presented): A compound of claim 19, of the formula:

 H_2 -R-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy) propylamide;

(H) (CH₃CO) -ß-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy) propylamide;

(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-ß-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-ß-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

 H_2 -R-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy) propylamide;

(H) (CH₃CO)-ß-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy) propylamide;

Filed: November 13, 2003

Page: 5

(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-ß-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-ß-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

 H_2 - \Re -Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy) propylamide;

(H) (CH₃CO) -ß-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy) propylamide;

(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-ß-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-(2R,3R-(2-hydroxymethyl)-3-

hydroxymethyl)propylamide;

(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-ß-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

 H_2 -R-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy) propylamide;

(H) (CH₃CO)-S-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy) propylamide;

(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-ß-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-ß-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

Filed: November 13, 2003

Page:

H₂-Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy) propylamide;

(H) (CH₃CO) Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-(2R, 3R-(2-

hydroxymethy1)-3-hydroxy)propylamide;

(H)(4-(2-hydroxyethyl)-1-piperazinylacetyl)Phe-D-Cys-Tyr-D-

Trp-Lys-Val-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)Phe-D-Cys-

Tyr-D-Trp-Lys-Val-Cys-(2R,3R-(2-hydroxymethyl)-3-

hydroxy) propylamide;

 H_2 -Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy) propylamide;

H(CH,CO)Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-(2R,3R-(2-

hydroxymethyl)-3-hydroxy)propylamide;

(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)Phe-D-Cys-Pal-D-

Trp-Lys-Val-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)Phe-D-Cys-Pal-

D-Trp-Lys-Val-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

H₂-Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H) (CH,CO) Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-(2R,3R-(2-

hydroxymethyl)-3-hydroxy)propylamide;

(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)Phe-D-Cys-Tyr-D-

Trp-Lys-Thr-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)Phe-D-Cys-Tyr-

D-Trp-Lys-Thr-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

```
Applicant : Coy et al.

Serial No. : 10/712,081

Filed : November 13, 2003
```

naphthyl) ethylamide;

Page H,-Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy) propylamide; (H) (CH,CO) Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-(2R, 3R-(2hydroxymethyl)-3-hydroxy)propylamide; (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy)propylamide; (H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl) Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy)propylamide; H,-S-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide; (H) (CH,CO) - \(\text{S-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-} \) (2naphthyl) ethylamide; (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-ß-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide; (H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-ß-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide; H.-S-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide; (H) (CH,CO) - S-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2naphthyl)ethylamide; (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-\$-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide; (H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-ß-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide; H,-ß-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide; (H) (CH,CO) - R-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-

Filed: November 13, 2003

Page:

(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-ß-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;

(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-ß-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;

H.-S-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;

(H) (CH₃CO)-S-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-

naphthyl)ethylamide;

(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-ß-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;

(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-ß-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;

H,-Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;

(H) (CH₃CO) Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-

naphthyl)ethylamide;

(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;

(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;

H,-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;

(H) (CH₃CO) Phe-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-

naphthyl)ethylamide;

(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;

(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;

Coy et al.

Serial No. :

10/712,081

November 13, 2003

Filed Page

Q

```
H<sub>2</sub>-Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;

(H) (CH<sub>2</sub>CO) Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-
```

naphthyl) ethylamide;

(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl) Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl) ethylamide;

(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;

 H_2 -Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;

(H) (CH $_3$ CO) Phe-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-

naphthyl) ethylamide;

(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl) Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl) ethylamide;

(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl) Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl) ethylamide;

H,-ß-Nal-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-2R-(2-naphthyl)ethylamide;

H₂-Phe-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-2R-(2-naphthyl)ethylamide;

 H_2 -R-Nal-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide; or

 H_2 -Phe-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy) propylamide;

or a pharmaceutically acceptable salt thereof.

23 (previously presented): A compound of the formula:

$$R_1$$

$$A^1-A^2-A^3-D-Trp-Lys-A^6-A^7-A^8-R_3$$

$$R_2$$

Coy et al.

Serial No. :

10/712,081

Filed

November 13, 2003

Page :

wherein

A¹ is a D- or L-isomer of an aromatic amino acid, or is deleted;

A² is a D-aromatic amino acid,

A' is an aromatic amino acid;

A⁶ is Thr, Thr(Bzl), Gly, Ser, an Eaa, or an aliphatic amino acid;

 A^7 is an aromatic amino acid or an aliphatic amino acid; A^8 is a D- or L-isomer selected from the group consisting of

Thr, Ser, an aromatic amino acid, or an aliphatic amino acid;

each of R_1 and R_2 , is, independently, H or substituted or unsubstituted lower alkyl, aryl, aryl lower alkyl, heterocycle, heterocycle lower alkyl, E_1SO_2 or E_1CO wherein E_1 , is aryl, aryl lower alkyl, heterocycle, or heterocycle lower alky and said substituent is halo, lower alkyl, hydroxy, halo lower alkyl, or hydroxy lower alkyl; and

 R_3 is OH, NH_2 , C_{1-12} alkoxy, or $NH-Y-CH_2-Z$, wherein Y is a C_{1-12} hydrocarbon moiety and Z is H, OH, CO_2H , or $CONH_2$, or R_3 , together with the carbonyl group of A^8 attached thereto, are reduced to form H, lower alkyl, or hydroxy lower alkyl.

24 (previously presented): A compound of claim 23, wherein A^1 is an L- amino acid and A^2 is a D-aromatic amino acid.

25 (previously presented): A compound of claim 24, wherein each of A^1 , A^3 , and A^7 , is, independently, A^3 -Nal, o-X-Phe wherein X is H, OH, CH₃, halo, OCH₃, NH₂, CN or NO₂, p-X-Phe

Filed: November 13, 2003

Page : 11

wherein X is H, OH, CH₃, halo, OCH₃, NH₂, CN or NO₂, m-X-Phe wherein X is H, OH, CH₃, halo, OCH₃, NH₂, CN, or NO₂, F₅-Phe, Trp, Dip, 2-Pal, Tyr(Bzl), His, Igl, Tyr(I), Bta, Bip, Npa, or Pal; A² is D-ß-Nal, D-o-X-Phe wherein X is H, OH, CH₃, halo, OCH₃, NH₂, CN, or NO₂, D-p-X-Phe wherein X is H, OH, CH₃, halo, OCH₃, NH₂, CN, or NO₂, D-m-X-Phe wherein X is H, OH, CH₃, halo, OCH₃, NH₂, CN, or NO₂, D-F₅-Phe, D-Trp, D-Dip, D-2-Pal, D-Tyr(Bzl), D-His, D-Igl, D-Tyr(I), D-Bta, D-Bip, D-Npa, or D-Pal; A⁶ is Thr, Ser, Tle, Thr(Bzl), Abu, Ala, Ile, Leu, Gly, Nle, ß-Ala, Gaba, or Val; and A⁸ is the D- or L-isomer of Thr, Dip, F₅-Phe, p-X-Phe wherein X is H, OH, CH₃, halo, OCH₃, NH₂, CN, or NO₂, o-X-Phe wherein X is H, OH, CH₃, halo, OCH₃, NH₂, CN, or NO₂, m-X-Phe wherein X is H, OH, CH₃, halo, OCH₃, NH₂, CN, or NO₂, m-X-Phe wherein X is H, OH, CH₃, halo, OCH₃, NH₂, CN, or NO₂, Igl, Tyr (Bzl), or ß-Nal.

26 (previously presented): A compound of claim 25, wherein A^1 is B-Nal or Phe, A^2 is D-Cpa or D-Phe; A^3 is Phe or Tyr; A^6 is Abu, Thr, or Val; A^7 is Phe; and A^8 is Thr; R_1 is H, CH_3CO , 4-(2-hydroxyethyl)-1-piperazinylacetyl, or 4-(2-hydroxyethyl)-1-piperizineethanesulfonyl; R_2 is H; and R_3 is NH_2 .

27 (previously presented): A compound of claim 25 of the formula:

H₂-Phe-D-Phe-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH₂;

H₂-Phe-D-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH₂;

H₂-Phe-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH₂;

H₂-S-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH₂;

(H) (CH,CO)-S-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH,;

```
Serial No. :
                 10/712,081
                 November 13, 2003
Filed
Page
      (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-ß-Nal-D-Cpa-Tyr-
D-Trp-Lys-Val-Phe-Thr-NH,;
      (H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-ß-Nal-D-
Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH,;
     H,-ß-Nal-D-Cpa-Pal-D-Trp-Lys-Val-Phe-Thr-NH,;
      (H) (CH,CO) - R-Nal-D-Cpa-Pal-D-Trp-Lys-Val-Phe-Thr-NH,;
      (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-ß-Nal-D-Cpa-Pal-
D-Trp-Lys-Val-Phe-Thr-NH,;
      (H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-ß-Nal-D-
Cpa-Pal-D-Trp-Lys-Val-Phe-Thr-NH,;
     H,-ß-Nal-D-Cpa-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH,;
      (H) (CH,CO) - \( \mathbb{G} - \mathbb{Nal} - \mathbb{D} - \mathbb{Cpa} - \mathbb{Tyr} - \mathbb{D} - \mathbb{Trp} - \mathbb{Lys} - \mathbb{Thr} - \mathbb{Phe} - \mathbb{Thr} - \mathbb{NH}_2;
      (H)(4-(2-hydroxyethyl)-1-piperazinylacetyl)-ß-Nal-D-Cpa -
Tyr-D-Trp-Lys-Thr-Phe-Thr-NH,;
      (H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-ß-Nal-D-
Cpa-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH,;
     H<sub>2</sub>-$-Nal-D-Cpa-Pal-D-Trp-Lys-Thr-Phe-Thr-NH,;
      (H) (CH,CO) - R-Nal-D-Cpa-Pal-D-Trp-Lys-Thr-Phe-Thr-NH,;
      (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-ß-Nal-D-Cpa-Pal-
D-Trp-Lys-Thr-Phe-Thr-NH,;
      (H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-ß-Nal-D-
Cpa-Pal-D-Trp-Lys-Thr-Phe-Thr-NH,;
```

H,-ß-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-ß-Nal-NH,;

Applicant :

Coy et al.

Coy et al.

Serial No. :

10/712,081

November 13, 2003

Filed

Page

13

(H) (CH,CO) - S-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-S-Nal-NH,;

(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-ß-Nal-D-Cpa Tyr-D-Trp-Lys-Val-Phe-ß-Nal-NH,;

(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-\$\mathbb{S}-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-\mathbb{S}-Nal-NH₂;

H,-ß-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-ß-Nal-NH2; or

 $\rm H_2-R-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH_2;$ or a pharmaceutically acceptable salt thereof.

28 (original): A compound of claim 23, wherein A^1 is a D-amino acid and A^2 is a D-aromatic amino acid.

29 (previously presented): A compound of claim 28, wherein each of A¹ and A², is, independently, D-ß-Nal, D-o-X-Phe wherein X is H, OH, CH, halo, OCH, NH, CN, or NO, D-p-X-Phe wherein X is H, OH, CH, halo, OCH, NH, CN, or NO, D-m-X-Phe wherein X is H, OH, CH, halo, OCH, NH, CN, or NO, D-F,-Phe, D-Trp, D-Dip, D-2-Pal, D-Tyr(Bzl), D-His, D-Igl, D-Tyr(I), D-Bta, D-Bip, D-Npa, or D-Pal; each of A³ and A⁷, independently, is ß-Nal, o-X-Phe wherein X is H, OH, CH, halo, OCH, NH, CN, or NO, p-X-Phe wherein X is H, OH, CH, halo, OCH, NH, CN, or NO, m-X-Phe wherein X is H, OH, CH, halo, OCH, NH, CN, or NO, F5-Phe, Trp, Dip, 2-Pal, His, Igl, Tyr(I), Bta, Bip, Npa, Tyr(Bzl), or Pal; A⁶ is Thr, Ser, Tle, Thr(Bzl), Abu, Ala, Ile, Leu, Gly, Nle, $\text{$\mathbb{S}$-Ala, Gaba, or Val; and \mathbb{A}^{8} is the D- or L-isomer of Thr, Dip, F_{s}-$ Phe, p-X-Phe wherein X is H, OH, CH, halo, OCH, NH, CN, or NO, o-X-Phe wherein X is H, OH, CH, halo, OCH, NH, CN, or NO, m-X-

Coy et al.

Serial No. : Filed : 10/712,081 November 13, 2003

Page

14

Phe wherein X is H, OH, CH₃, halo, OCH₃, NH₂, CN, or NO₂, Igl, Tyr(Bzl), or ß-Nal.

30 (previously presented): A compound of claim 29, wherein A^1 is D-B-Nal or D-Phe; A^2 is D-Cpa or D-Phe; A^3 is Phe or Tyr; A^6 is Thr or Val; A^7 is Phe; A^8 is Thr; R_1 is H, CH_3CO , 4-(2-hydroxyethyl)-1-piperazinylacetyl, or 4-(2-hydroxyethyl)-1-piperizineethanesulfonyl; R_2 is H; and R_3 is NH_2 .

31 (previously presented): A compound of claim 29 of the formula:

H,-D-S-Nal-D-Cpa-Phe-D-Trp-Lys-Val-Phe-Thr-NH,;

H,-D-ß-Nal-D-Phe-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH,;

H,-D-Phe-D-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH,;

H,-D-&-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH,;

 $\rm H_2-D-S-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-S-Nal-NH_2;$ or a pharmaceutically acceptable salt thereof.

32 (previously presented): A method of promoting the release of growth hormone in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim 18 or a pharmaceutically acceptable salt thereof.

33 (previously presented): A method of promoting the release of insulin in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim 18 or a pharmaceutically acceptable salt thereof.

Coy et al.

Serial No. :

10/712,081 November 13, 2003

Filed Page

15

34 (previously presented): A method of enhancing wound healing in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim 18 or a pharmaceutically acceptable salt thereof.

- 35 (previously presented): A method of promoting angiogenesis in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim 18 or a pharmaceutically acceptable salt thereof.
- 36 (previously presented): A method of imaging cells having somatostatin receptors which comprises administering to a subject an effective amount of a compound or a pharmaceutically acceptable salt thereof according to claim 18 having Tyr(I).
- 37 (previously presented): A method of eliciting an antagonist effect from a somatostatin receptor in a subject, which comprises administering to said subject an effective amount of a compound according to claim 18 or a pharmaceutically acceptable salt thereof.
- 38 (previously presented): A method of promoting the release of growth hormone in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim 23 or a pharmaceutically acceptable salt thereof.

Filed: November 13, 2003

Page : 16

39 (previously presented): A method of promoting the release of insulin in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim 23 or a pharmaceutically acceptable salt thereof.

- 40 (previously presented): A method of enhancing wound healing in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim 23 or a pharmaceutically acceptable salt thereof.
- 41 (previously presented): A method of promoting angiogenesis in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim 23 or a pharmaceutically acceptable salt thereof.
- 42 (previously presented): A method of imaging cells having somatostatin receptors which comprises administering to a subject an effective amount of a compound or a pharmaceutically acceptable salt thereof according to claim 23 having Tyr(I).
- 43 (previously presented): A method of eliciting an antagonist effect from a somatostatin receptor in a subject, which comprises administering to said subject an effective amount of a compound according to claim 23 or a pharmaceutically acceptable salt thereof.

Coy et al. 10/712,081

Serial No. : Filed :

November 13, 2003

Page

17

44 (previously presented): A compound of claim 18, wherein A^8 is a D- or L-isomer of Thr or B-Nal; and R_3 , together with A^8 , form (2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide or 2R-(2-naphthyl)ethylamide; or a pharmaceutically acceptable salt thereof.